Skip to main content
PMC home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2001 Jan;16(1):42–51. doi: 10.1007/BF02867567

Status of epidermal growth factor receptors family in hormone-dependent carcinomas of the breast and prostate with reference to serum lipids and lipoproteins

D Jain 1, A Ray 2, A K Bahadur 1, K U Chaturvedi 3, R Sood 4, S Sharma 2, S L D Naik 2, B K Sharma 2,✉
PMCID: PMC3453600  PMID: 23105291

Abstract

There are numerous growing evidences of resemblance between carcinomas of the breast and prostate. A total of 45 cases of these two hormone-dependent cancers along with appropriate controls were subjected for status of epidermal growth factor receptors as well as serum lipid profile. Paraffin embedded tissue sections from aforesald tumours were analysed by immunohistochemical staining for epidermal growth factor receptor (EGF-R), c-erbB-2 oncoprotein, estrogen receptor (ER) and progesterone receptor (PgR). Sera from same individuals were studied for serum lipid profile analysis. The study revealed that immunoexpression of all receptor proteins (EGF-R). c-erbB-2 was significantly higher in breast carcinoma. In addition, mean levels of triglycerides, total cholesterol, LDL-cholesterol were found to be significantly elevated while the level of HDL-cholesterol was observed to be lower among patients with breast cancer as compared to matched controls. Further, ER-positive breast cancer cases have significantly higher mean level of HDL-cholesterol when compared with ER-negative breast cancer patients. Contrary to this, no alteration in different serum lipid fractions was noticed among the patients with prostate cancer. However, a positive relationship was noticed between immunoexpressions of EGF-R and c-erbB-2 in prostate cancer.

Key words: EGF-R, c-erbB-2, lipids, breast cancer and prostate cancer

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

References

  • 1.Pont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. New Engl. J. Med. 1985;312:146–151. doi: 10.1056/NEJM198501173120303. [DOI] [PubMed] [Google Scholar]
  • 2.Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 1993;15:48–65. doi: 10.1093/oxfordjournals.epirev.a036116. [DOI] [PubMed] [Google Scholar]
  • 3.Hulka B.S., Stark A.T. Breast cancer: cause and prevention. Lancet. 1995;346:883–887. doi: 10.1016/S0140-6736(95)92713-1. [DOI] [PubMed] [Google Scholar]
  • 4.Persky V.W., Chatterton R.T., Hom L.V., Grant M.D., Langenberg P., Marvin J. Hormone levels in vegetarian and nonvegetarian teenage girls: potential implications for breast cancer risk. Cancer Res. 1992;52:578–583. [PubMed] [Google Scholar]
  • 5.Knapp M.L., Al-Sheibani S., Riches P.G. Alterations of serum lipids in breast cancer: effects of disease activity, treatment and hormonal factors. Clin. Chem. 1991;37:2093–2101. [PubMed] [Google Scholar]
  • 6.Boyd N.F., Connelly P., Lynch H., Knaus M., Michal S., Fili M., Martin L.J., Lockwood G., Tritchler D. Plasma lipids, lipoproteins, and familial breast cancer. Cancer Epidemiol. Biomarkers Prev. 1995;4:117–122. [PubMed] [Google Scholar]
  • 7.Bahadur A.K., Yadav R., Ray A., Pasha S.T., Sharma S., Sharma B.K. Alteration in serum lipids and host cell mediated immune response in patients of carcinoma breast before, during and after treatment. J. Basic Appl. Biomed. 1998;6:19–24. [Google Scholar]
  • 8.Fishman J., Osborne M.P., Telang N.T. The role of estrogen in mammary carcinogenesis. Ann. N. Y. Acad. Sci. 1995;768:91–100. doi: 10.1111/j.1749-6632.1995.tb12113.x. [DOI] [PubMed] [Google Scholar]
  • 9.Bortoli M., Maggiora P., Capello D., Antoniotti S., Saviozzi S., Sapei M.L., Dati C. Hormonal control of growth factor receptor expression. Ann. N. Y. Acad. Sci. 1996;784:336–348. doi: 10.1111/j.1749-6632.1996.tb16248.x. [DOI] [PubMed] [Google Scholar]
  • 10.Sharma B.K., Ray A., Kaur S., Gupta S. Immunohistochemical co-expression of c-erbB-2/New oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Indian J. Exp. Biol. 1999;37:223–227. [PubMed] [Google Scholar]
  • 11.Fox S.B., Persad R.A., Coleman N., Day C.A., Silcocks P.B., Collins C.C. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) protatic adenocarcinoma. Br. J. Urol. 1994;74:214–220. doi: 10.1111/j.1464-410X.1994.tb16589.x. [DOI] [PubMed] [Google Scholar]
  • 12.Kukuho M., Yoshiki T., Hamagucha A., Okada Y., Tomoyoshi T., Higuchi K. Immunohistochemical study of c-erbB-2 proto-oncogene product in prostate cancer. Jpn. J. Urol. 1993;84:1872–1878. doi: 10.5980/jpnjurol1989.84.1872. [DOI] [PubMed] [Google Scholar]
  • 13.Ries L.A.G., Hankey B.D., Edwards B.K. Cancer statistics review 1973–87. N.I.H. Publ. 1990;90:2789–2789. [Google Scholar]
  • 14.Marchand L., Kolonel L.N., Wilkens L.R. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiol. 1994;5:276–282. doi: 10.1097/00001648-199405000-00004. [DOI] [PubMed] [Google Scholar]
  • 15.Ratnakar N., Sharma B.K., Chaturvedi K.U., Kaur S., Naik S.L.D., Ray A. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre-and postmenopausal breast cancer. A.P.M.I.S. 1998;106:1075–1080. doi: 10.1111/j.1699-0463.1998.tb00261.x. [DOI] [PubMed] [Google Scholar]
  • 16.Allan C.C., Poon L.S., Chan C.G.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974;20:470–475. [PubMed] [Google Scholar]
  • 17.Wahlefield A.W. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer H., editor. Methods of enzymatic analysis, Vol II. New York: Academic Press; 1974. pp. 1831–1831. [Google Scholar]
  • 18.Lopes-Virella M.F., Stone P., Ellis S., Colwell J.A. Cholesterol determinations in highdensity lipoproteins separated by three different methods. Clin. Chem. 1977;23:882–884. [PubMed] [Google Scholar]
  • 19.Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 20.Peles E., Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bio. Essays. 1993;15:815–824. doi: 10.1002/bies.950151207. [DOI] [PubMed] [Google Scholar]
  • 21.Lipponen H.J., Aaltomaa S., Syrjanen S., Syrjanen K. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res. 1993;13:1147–1152. [PubMed] [Google Scholar]
  • 22.Ioachim E., Kamina S., Athanassiadou S., Agnahtis N.J. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res. 1996;16:3141–3147. [PubMed] [Google Scholar]
  • 23.Koutselini H., Markopoulos C., Lambroupoulou S., Gogas H., Kandaraki C., Gogas J. Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cnacer patients. Cytopathol. 1995;6:14–21. doi: 10.1111/j.1365-2303.1995.tb00003.x. [DOI] [PubMed] [Google Scholar]
  • 24.Wiltschke C., Kindas-Muegge J., Steininger A., Reiner A., Reiner G., Preis P.N. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J. Cancer Res. Clin. Oncol. 1994;120:737–742. doi: 10.1007/BF01194273. [DOI] [PubMed] [Google Scholar]
  • 25.Rudas M., Neumayer R., Gnant M.F., Mittelbock M., Jakesz R., Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur. J. Cancer. 1997;33:39–44. doi: 10.1016/S0959-8049(96)00368-1. [DOI] [PubMed] [Google Scholar]
  • 26.Hiatt A., Friedman G.D., Bawol R.D., Ury H.K. Breast cancer and serum cholesterol. J. Natl. Cancer Inst. 1982;68:885–889. [PubMed] [Google Scholar]
  • 27.Agurs-Collins T., Kim K.S., Dunston G.M., Adams C.L.L. Plasma lipid alterations in African-American women with breast cancers. J. Cancer Res. Clin. Oncol. 1998;124:186–190. doi: 10.1007/s004320050153. [DOI] [PubMed] [Google Scholar]
  • 28.Qi X.Y., Zhang A.Y., Wu G.L., Pang W.Z. The association between breast cancer and diet and other factors. Asia Pacific J. Public Health. 1994;7:98–104. doi: 10.1177/101053959400700204. [DOI] [PubMed] [Google Scholar]
  • 29.Goodwin P.J., Boyd N.F., Hanna W., Hartwick W., Murray D., Qizilbash A., Redwood S., Hood N., Delgiudice M.E., Sidlofsky S., Cready D., Wilkinson R., Mahoney L., Connelly P., Page D.L. Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. Nutr. Cancer. 1997;27:284–292. doi: 10.1080/01635589709514539. [DOI] [PubMed] [Google Scholar]
  • 30.Takatani O., Okumoto T., Kosano H. Genesis of breast cancer in Japanese: a possible relationship between sex hormone binding globulin (SHBG) and serum lipid components. Breast Cancer Res. Treat. 1991;18(Suppl 1):27–29. doi: 10.1007/BF02633523. [DOI] [PubMed] [Google Scholar]
  • 31.Hoyer A.P., Engholm G. Serum lipids and breast cancer risk: a cohort study of 5207 Danish women. Cancer Causes Control. 1992;3:403–408. doi: 10.1007/BF00051352. [DOI] [PubMed] [Google Scholar]
  • 32.Maygarden S., Strom S., Ware J. Localization of EGFR by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia and benign hyperplasia. Arch. Pathol. Lab. Med. 1992;116:269–273. [PubMed] [Google Scholar]
  • 33.Ibrahim G., Kerri B., Mac Donald J., Ibrahim S., Kinney R., Humphrey P., Robertson C. Different immunoreactivity of EGFR in benign, dysplastic and malignant prostate tissue. J. Urol. 1993;149:170–173. doi: 10.1016/s0022-5347(17)36032-9. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES